JP2018528945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528945A5 JP2018528945A5 JP2018510089A JP2018510089A JP2018528945A5 JP 2018528945 A5 JP2018528945 A5 JP 2018528945A5 JP 2018510089 A JP2018510089 A JP 2018510089A JP 2018510089 A JP2018510089 A JP 2018510089A JP 2018528945 A5 JP2018528945 A5 JP 2018528945A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- measuring
- renal
- composition
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210031P | 2015-08-26 | 2015-08-26 | |
| US62/210,031 | 2015-08-26 | ||
| PCT/US2016/048603 WO2017035319A1 (en) | 2015-08-26 | 2016-08-25 | Methods for treatment of polycystic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528945A JP2018528945A (ja) | 2018-10-04 |
| JP2018528945A5 true JP2018528945A5 (https=) | 2019-10-03 |
| JP6929269B2 JP6929269B2 (ja) | 2021-09-01 |
Family
ID=56855838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510089A Active JP6929269B2 (ja) | 2015-08-26 | 2016-08-25 | 多発性嚢胞腎の処置のための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10633657B2 (https=) |
| EP (2) | EP4268891A3 (https=) |
| JP (1) | JP6929269B2 (https=) |
| KR (2) | KR20250049446A (https=) |
| CN (2) | CN108135922A (https=) |
| AU (1) | AU2016312590B2 (https=) |
| CA (1) | CA2995996A1 (https=) |
| DK (1) | DK3340993T5 (https=) |
| ES (1) | ES2954151T3 (https=) |
| IL (1) | IL257596B (https=) |
| MA (1) | MA44836A (https=) |
| MX (1) | MX2018002354A (https=) |
| RU (1) | RU2742300C2 (https=) |
| WO (1) | WO2017035319A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106568A1 (en) * | 2016-12-05 | 2018-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
| IL322679A (en) * | 2016-12-05 | 2025-10-01 | Regulus Therapeutics Inc | Modified oligonucleotides for the treatment of polycystic kidney disease |
| EP3841220A1 (en) | 2018-08-23 | 2021-06-30 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
| CA3234547A1 (en) | 2021-10-08 | 2023-04-13 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| WO2024026354A2 (en) * | 2022-07-27 | 2024-02-01 | The General Hospital Corporation | Methods and compositions for use in treating autosomal recessive polycystic kidney disease (arpkd) |
| IL324441A (en) * | 2023-06-16 | 2026-01-01 | Pyc Therapeutics Ltd | Compounds and methods for treating kidney diseases |
| WO2025110217A1 (ja) * | 2023-11-22 | 2025-05-30 | 国立大学法人東海国立大学機構 | 嚢胞性腎疾患の予防及び／又は治療剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| NZ549535A (en) | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| JPWO2007126150A1 (ja) * | 2006-04-27 | 2009-09-17 | 国立大学法人名古屋大学 | 癌の新規治療用組成物 |
| US20120283411A9 (en) * | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| US20090105174A1 (en) * | 2007-04-20 | 2009-04-23 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| WO2014082644A1 (en) * | 2012-11-30 | 2014-06-05 | WULFF, Peter, Samuel | Circular rna for inhibition of microrna |
| US10660890B2 (en) * | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| EP3105327A4 (en) * | 2014-02-12 | 2017-10-18 | Thomas Jefferson University | Compositions and methods of using microrna inhibitors |
| WO2018106568A1 (en) | 2016-12-05 | 2018-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
| IL322679A (en) | 2016-12-05 | 2025-10-01 | Regulus Therapeutics Inc | Modified oligonucleotides for the treatment of polycystic kidney disease |
-
2016
- 2016-08-25 DK DK16760627.6T patent/DK3340993T5/da active
- 2016-08-25 KR KR1020257010343A patent/KR20250049446A/ko active Pending
- 2016-08-25 AU AU2016312590A patent/AU2016312590B2/en active Active
- 2016-08-25 RU RU2018108206A patent/RU2742300C2/ru active
- 2016-08-25 MA MA044836A patent/MA44836A/fr unknown
- 2016-08-25 EP EP23179064.3A patent/EP4268891A3/en not_active Withdrawn
- 2016-08-25 JP JP2018510089A patent/JP6929269B2/ja active Active
- 2016-08-25 WO PCT/US2016/048603 patent/WO2017035319A1/en not_active Ceased
- 2016-08-25 KR KR1020187007997A patent/KR20180080181A/ko not_active Ceased
- 2016-08-25 IL IL257596A patent/IL257596B/en unknown
- 2016-08-25 CN CN201680049290.6A patent/CN108135922A/zh active Pending
- 2016-08-25 EP EP16760627.6A patent/EP3340993B1/en active Active
- 2016-08-25 CA CA2995996A patent/CA2995996A1/en active Pending
- 2016-08-25 MX MX2018002354A patent/MX2018002354A/es unknown
- 2016-08-25 CN CN202111177217.6A patent/CN114404440A/zh active Pending
- 2016-08-25 US US15/753,865 patent/US10633657B2/en active Active
- 2016-08-25 ES ES16760627T patent/ES2954151T3/es active Active
-
2020
- 2020-03-19 US US16/823,904 patent/US11168325B2/en active Active
-
2021
- 2021-10-05 US US17/494,234 patent/US20220025372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528945A5 (https=) | ||
| JP2015536301A5 (https=) | ||
| RU2018108206A (ru) | Способы лечения поликистозной болезни почек | |
| Szabo et al. | Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat | |
| Wilflingseder et al. | miR-182-5p inhibition ameliorates ischemic acute kidney injury | |
| CN101237880B (zh) | 通过vegf拮抗剂的皮下给药治疗疾病 | |
| JP2019536803A5 (https=) | ||
| JP2019501935A5 (https=) | ||
| Kusumoto et al. | Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models | |
| JP2018507244A5 (https=) | ||
| WO2004075852A2 (en) | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | |
| Fan et al. | Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan | |
| WO2019028055A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AC T-LYMPHOBLASTIC LYMPHOBLASTIC LEUKEMIA | |
| Roberts et al. | Adenosine receptor expression in the development of renal fibrosis following ischemic injury | |
| CA2972076A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| Budu et al. | Renal fibrosis due to multiple cisplatin treatment is exacerbated by kinin B1 receptor antagonism | |
| JP2020518633A5 (https=) | ||
| Valdes et al. | Segmental heterogeneity in Bcl‐2, Bcl‐xL and Bax expression in rat tubular epithelium after ischemia‐reperfusion | |
| McFarlane et al. | Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines | |
| Qian et al. | Inhibition of WISE preserves renal allograft function | |
| Tan et al. | Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats | |
| US20200316067A1 (en) | Combination of raf inhibitors and taxanes | |
| SHELDON HIRSCH | An update on proteinuric chronic kidney disease: The dual-goal approach | |
| Levy et al. | Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials | |
| Chadjichristos et al. | Reversibility of renal fibrosis |